Caring for the Ages
A Joint Online Publication
The Foundation For Post-Acute and Long-Term Care Medicine
PALTmed

April 6, 2026

OIG Launches Nursing Home Opioid Investigation: What Medical Directors Need to Know Now

By Ronald Rosen, MD, CWSP, CMD



The Office of Inspector General (OIG) for the U.S. Department of Health and Human Services has announced a new investigation examining possible opioid overuse, misuse, or diversion in nursing homes. While federal scrutiny of psychotropics in long-term care is familiar terrain, this initiative signals renewed regulatory attention on opioid prescribing, pharmacy controls, and state oversight mechanisms within skilled nursing facilities (SNFs).

For nursing home medical directors, this development is not merely an enforcement headline—it is a call to operational readiness.

Why This Investigation Matters

Opioids remain clinically necessary in post-acute and long-term care. Residents with advanced osteoarthritis, vertebral compression fractures, metastatic cancer, ischemic limb disease, and end-stage conditions frequently require opioid analgesics for humane symptom control. However, opioids are simultaneously a high-risk medication class from regulatory, diversion, and adverse event perspectives.

The OIG's review is expected to examine:

- Prescribing patterns and duration of therapy
- Documentation of indication and functional benefit
- Pharmacy consultant oversight
- Facility-level diversion prevention systems
- State survey agency monitoring processes
- Potential billing implications under Medicare and Medicaid

This is consistent with broader federal enforcement priorities involving opioids, including diversion cases prosecuted by the Drug Enforcement Administration and program integrity reviews affecting facilities reimbursed by the Centers for Medicare & Medicaid Services (CMS).

The Regulatory Framework: What Surveyors Already Expect

Medical directors should assume that OIG investigators and state surveyors will evaluate opioid practices through the lens of:

- **F689** (Accident Hazards/Supervision)—fall risk related to sedation
- **F758** (Unnecessary Drugs)—appropriate indication, dose, duration
- **F761** (Storage of Drugs and Biologicals)—diversion safeguards
- **F755** (Pharmacy Services)—consultant pharmacist oversight

Unlike antipsychotic scrutiny, opioids do not carry mandated gradual dose reduction requirements. However, surveyors increasingly expect:

1. Clear documentation of pain assessment
2. Evidence of non-opioid modalities trialed when appropriate
3. Ongoing reassessment of benefit vs. harm
4. Functional outcomes, not simply numeric pain scores

Clinical Reality: The Ethical Tension

Medical directors must balance two competing risks:

- Overprescribing: sedation, falls, respiratory depression, regulatory citations.
- Undertreating pain: functional decline, behavioral symptoms, suffering, potential allegations of neglect.

In palliative and end-stage disease, opioids are often the safest effective analgesic option compared with NSAIDs (renal/GI risk) or certain centrally acting alternatives. The Beers Criteria highlight multiple medication classes as potentially inappropriate in older adults, but opioids remain appropriate when clinically justified and carefully monitored.

The investigation should not lead to reflexive opioid deprescribing. Rather, it should prompt disciplined prescribing.

Diversion Risk in the Nursing Home Setting

Unlike outpatient settings, SNFs involve multiple handling points:

- Prescriber
- Pharmacy
- Delivery chain

- Medication room storage
- Nurse administration
- Waste documentation

Common vulnerabilities include:

- Incomplete witnessed waste
- PRN stock discrepancies
- Delayed reconciliation after discharge or death
- Weak automated dispensing analytics

Medical directors should collaborate with the following members of the interdisciplinary team to review internal controls before regulators do:

- Director of nursing
- Consultant pharmacist
- Compliance officer
- Administrator

Practical Action Plan for Medical Directors

Conduct an Internal Opioid Audit--Review:

- Residents on scheduled opioids for over 30 days
- High morphine milligram equivalent (MME) cases
- PRN frequency exceeding expected use
- Concurrent benzodiazepine or gabapentinoid use

Strengthen Documentation Standards--Require documentation of:

- Indication (specific diagnosis)
- Functional impact
- Reassessment intervals
- Side effect monitoring
- Risk/benefit discussion

Clarify Facility Opioid Stewardship Policy--Develop or update a written protocol addressing:

- Initiation criteria
- Monitoring expectations

- Safe storage
- Diversion reporting pathway
- End-of-life exception framework

Prepare for Data Requests--OIG audits frequently request:

- Claims data
- Consultant pharmacist reports
- Incident logs
- Medication error documentation
- Controlled substance reconciliation records

They also ensure records are complete, consistent, and contemporaneous.

Anticipated Outcomes of the OIG Review

Historically, OIG investigations result in one or more of the following:

- Recommendations to CMS for regulatory clarification
- State survey guidance revisions
- Increased targeted facility audits
- Data-driven flagging of prescribing outliers
- Referral of egregious cases for enforcement

Medical directors should expect heightened scrutiny of facilities with outlier opioid utilization patterns relative to case mix.

Strategic Perspective: This Is About Systems, Not Just Prescribers

Opioid risk in nursing homes is rarely a single-physician issue. It is a systems issue involving:

- Pain assessment culture
- Interdisciplinary communication
- Pharmacy oversight
- Compliance infrastructure
- Staff education

Medical directors who approach this proactively—framing opioid stewardship as quality improvement rather than defensive medicine—will be better positioned both clinically and legally.

Final Takeaway

The OIG investigation should not generate panic-driven opioid discontinuation. It should catalyze:

- Rational prescribing
- Improved documentation
- Stronger diversion safeguards
- Interdisciplinary accountability

Above all, it should reinforce a central principle of post-acute and long-term care medicine: relief of suffering and regulatory compliance are not mutually exclusive goals—but both require disciplined leadership.

References

1. U.S. Department of Health and Human Services Office of Inspector General. Work Plan Updates: Nursing Home Opioid Oversight. 2026.
2. Centers for Medicare & Medicaid Services. State Operations Manual Appendix PP – Guidance to Surveyors for Long Term Care Facilities.
3. American Geriatrics Society. 2023 Updated AGS Beers Criteria® for Potentially Inappropriate Medication Use in Older Adults.
4. CDC. 2022 Clinical Practice Guideline for Prescribing Opioids for Pain.
5. DEA Diversion Control Division. Practitioner's Manual.
6. OIG Reports on Opioid Monitoring in Medicare Part D and Long-Term Care Settings

Dr. Rosen is a geriatrician at Mass General Brigham and a hospice and palliative medicine physician at Care Dimensions Hospice and Palliative Care. He is a certified wound specialist and serves on the PALTmed Core Curriculum faculty.

https://paltmed.org/news-media/oig-launches-nursing-home-opioid-investigation-what-medical-directors-need-know-now